Products for Research Use Only
RegisterLogin

Doxycycline (hydrochloride)

CAT: 0804-HY-N0565A-01Size: 25 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-N0565A-01Size:25 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Doxycycline hydrochloride, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor[1]. Doxycycline hydrochloride shows antibacterial activity and anti-cancer cell proliferation activity. Doxycycline hydrochloride can be used to construct gene expression regulation models[1][2][3][4][5].
CAS Number
10592-13-9
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Antibiotic; Bacterial; MMP; Parasite
Type
Reference compound
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/doxycycline-hydrochloride.html
Purity
99.99
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C(C1=O)=C(O)[C@@H](N(C)C)[C@]2([H])[C@@H](O)[C@]3([H])[C@@H](C)C4=C(C(C3=C(O)[C@@]21O)=O)C(O)=CC=C4)N.Cl
Molecular Formula
C22H25ClN2O8
Molecular Weight
480.90
Precautions
H302, H315, H319, H335
References & Citations
[1]Wilfried Briest, et al. Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome. J Pharmacol Exp Ther. 2011 Jun;337 (3) :621-7.|[2]Eusebio Manchado, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016 Jun 30;534 (7609) :647-51.|[3]Anna-Luisa Luger, et al. Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems. Int J Mol Sci. 2018 May 17;19 (5) :1504.|[4]Ethan Ahler, et al. Doxycycline alters metabolism and proliferation of human cell lines. PLoS One. 2013 May 31;8 (5) :e64561.|[5]Le Zhang, et al. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle. 2017 Apr 18;16 (8) :737-745.|[6]Niv Y. Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis. Digestion. 2016;93 (2) :167-73.|[7]Manfredsson FP, et al. Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol Ther. 2009 Nov;17 (11) :1857-67.|[8]Kistner A, et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A. 1996 Oct 1;93 (20) :10933-8.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
Tetracycline
Citation 01
BioRxiv. 2025 Jun 19.|bioRxiv. 2025 May 14.|Cancer Lett. 2016 Jun 28;376 (1) :188-96.|Cell Death Differ. 2019 Nov;26 (11) :2400-2415. |Cell Rep. 2024 Aug 22;43 (9) :114662.|Cell Rep. 2025 Jul 26;44 (8) :116076.|Cell Rep. 2025 Nov 25;44 (11) :116496.|Cell. 2023 Feb 2;186 (3) :591-606.e23.|Chem Eng J. 2025 Oct 8;524:169421.|J Exp Clin Cancer Res. 2025 Mar 19;44 (1) :99.|Nat Cell Biol. 2025 Apr;27 (4) :641-653.|Neuron. 2025 Jul 23;113 (14) :2310-2324.e7.|Sci Adv. 2024 Apr 17;10 (16) :eadi1782|ACS Infect Dis. 2024 Apr 12;10 (4) :1327-1338.|Acta Pharmacol Sin. 2024 Nov;45 (11) :2420-2431.|Adv Sci (Weinh) . 2021 Mar 15;8 (10) :2004344.|Adv Sci (Weinh) . 2025 Jan 21:e2407942.|Adv Sci (Weinh) . 2025 Jun 17:e03865.|Adv Sci (Weinh) . 2025 Oct 13:e09383.|AMB Express. 2024 Dec 24;14 (1) :141.|Ann Lab Med. 2021 May 1;41 (3) :293-301.|Biochem Biophys Res Commun. 2022 Jul 30:615:163-171.|Biochem Pharmacol. 2025 Apr 12:116948.|Biol Res. 2024 Nov 24;57 (1) :90.|Biomed Pharmacother. 2023 Aug:164:114998.|bioRxiv. 2023 Jun 14:2023.06.13.544756.|bioRxiv. 2023 Mar 31:2023.03.29.534783.|bioRxiv. 2024 July 05.|bioRxiv. 2025 August 09.|Cancer Biol Ther. 2022 Dec 31;23 (1) :328-335.|Cancer Commun (Lond) . 2025 May;45 (5) :608-631.|Cancer Res. 2023 Oct 2;83 (19) :3220-3236.|Cancer Res. 2025 Feb 1;85 (3) :585-601.|Cell Commun Signal. 2022 Apr 12;20 (1) :52.|Cell Death Differ. 2023 Jul;30 (7) :1811-1828.|Cell Death Differ. 2025 Jul 5.|Cell Death Dis. 2020 May 7;11 (5) :331.|Cell Death Dis. 2022 Feb 10;13 (2) :138.|Cell Death Dis. 2025 Mar 12;16 (1) :170.|Cell Mol Life Sci. 2024 Nov 16;81 (1) :456.|Cell Mol Life Sci. 2025 Apr 6;82 (1) :139.|Cell Prolif. 2024 Feb;57 (2) :e13534.|Cell Rep. 2024 Jul 3;43 (7) :114431.|Cell Rep. 2025 May 26;44 (6) :115748.|Cell. 2025 Jun 26;188 (13) :3405-3421.e27.|Clin Exp Pharmacol Physiol. 2023 Jul;50 (7) :604-609.|Dev Cell. 2025 Apr 18:S1534-5807 (25) 00206-0.|Diagn Microbiol Infect Dis. 2025 Nov 4;114 (2) :117181.|Drug Resist Updat. 2024 Jun 24:76:101112.|Drug Resist Updat. 2026 Jan:84:101319.|EMBO Rep. 2025 Oct 20.|Emerg Microbes Infect. 2024 Dec;13 (1) :2321981.|FASEB J. 2020 Dec;34 (12) :16716-16735.|FASEB J. 2024 Apr 30;38 (8) :e23628.|Front Cell Infect Microbiol. 2021 Apr 28:11:640847.|Fundam Res. 2025 Jul 8.|Heliyon. 2024 May 30.|Infect Drug Resist. 2025 Apr 23:18:2005-2020.|Infect Drug Resist. 2025 Oct 4:18:5239-5247.|Inflammopharmacology. 2025 Apr;33 (4) :1935-1947.|Int Immunopharmacol. 2024 Jun 24:138:112518.|Int J Mol Med. 2020 Apr;45 (4) :1187-1194.|Int J Mol Sci. 2025 Mar 18;26 (6) :2712.|iScience. 2023 Mar 16;26 (4) :106421.|J Cell Mol Med. 2024 Sep;28 (17) :e70053.|J Cell Mol Med. 2025 Sep;29 (17) :e70815.|J Clin Invest. 2024 Jan 18;134 (5) :e171995.|J Med Virol. 2024 May;96 (5) :e29634.|J Med Virol. 2025 May;97 (5) :e70356.|J Neuroinflammation. 2025 Oct 11;22 (1) :230.|J Transl Med. 2024 Oct 10;22 (1) :923.|J Virol. 2024 Aug 30:e0133524.|Katedra farmakologie a toxikologie. 2020 Jul.|Microbiol Spectr. 2025 May 19:e0307424.|Mol Cancer. 2020 Mar 30;19 (1) :68.|Mol Cell. 2025 Jul 17;85 (14) :2654-2672.e7.|Mol Cell. 2025 Oct 2;85 (19) :3588-3604.e11.|Mol Oncol. 2024 May 22.|Molecules. 2023 Jul 26;28 (15) :5668.|Molecules. 2025 Jul 7;30 (13) :2881.|Nat Commun. 2024 Apr 6;15 (1) :2989.|Nat Genet. 2024 Feb;56 (2) :294-305.|Nat Microbiol. 2023 Mar;8 (3) :410-423.|Nat Protoc. 2025 Oct 8.|Neurobiol Stress. 2025 Oct 28:39:100768.|NPJ Parkinsons Dis. 2022 Aug 6;8 (1) :100.|Oncogene. 2024 Dec;43 (50) :3660-3672.|Oncogene. 2024 Feb;43 (6) :434-446.|Phytomedicine. 2024 Aug 22:134:155958.|PLoS Pathog. 2025 Jul 3;21 (7) :e1013258.|Redox Biol. 2023 Jun:62:102686.|Research Square Preprint. 2020 Jun.|Research Square Preprint. 2023 Jul 11.|Research Square Preprint. 2024 Apr 8.|Research Square Preprint. 2024 Jan 23.|Sci Adv. 2022 Jan 28;8 (4) :eabl5220.|Sci Adv. 2025 Jan 31;11 (5) :eadr8837.|Sci Signal. 2025 Mar 18;18 (878) :eadi5174.|Stem Cell Res Ther. 2024 Oct 8;15 (1) :350.|Theranostics. 2022 Mar 28;12 (7) :3131-3149.|Vet Microbiol. 2024 May:292:110046.|Virol Sin. 2022 Aug;37 (4) :558-568.|Water Res. 2023 Jul 15:240:120110.|Water. 2025 Jun 6.|Adv Sci (Weinh) . 2022 Aug;9 (22) :e2104823.|Adv Sci (Weinh) . 2024 Dec;11 (45) :e2404756.|Biochem Biophys Res Commun. 2022 Oct 15:625:23-30.|bioRxiv. 2019 Apr.|bioRxiv. 2024 Jan 23.|bioRxiv. 2025 April 15.|bioRxiv. 2025 January 15.|bioRxiv. 2025 July 10.|bioRxiv. 2025 March 25.|bioRxiv. 2025 Sep 10.|Cancer Commun (Lond) . 2024 Feb;44 (2) :251-272.|Cancer Res Commun. 2024 Jul 1;4 (7) :1815-1833.|Cell Death Dis. 2017 Mar 23;8 (3) :e2702.|Cell Death Dis. 2021 Apr 20;12 (5) :413.|Cell Discov. 2024 Nov 5;10 (1) :112.|Cell Mol Life Sci. 2025 Jun 5;82 (1) :224.|Cell Rep. 2021 Jun 8;35 (10) :109225.|Cell Rep. 2021 Sep 21;36 (12) :109739.|Cell Stem Cell. 2024 Jan 4;31 (1) :52-70.e8.|Elife. 2021 Oct 27;10:e65759.|EMBO Rep. 2025 Oct 20.|EMBO Rep. 2025 Sep 22.|FEBS Lett. 2025 Sep 1.|Food Funct. 2021 Dec 13;12 (24) :12535-12549.|Institute of Pharmacology and Toxicology University of Zürich. 2019 Nov.|J Biol Chem. 2022 Sep;298 (9) :102374.|J Biol Chem. 2023 May;299 (5) :104621.|J Genet Genomics. 2020 Nov 20;47 (11) :705-712.|Mol Cancer. 2020 Sep 9;19 (1) :139.|Mol Cell. 2025 Apr 17;85 (8) :1589-1605.e12.|Nat Commun. 2023 Dec 20;14 (1) :8461.|Nat Commun. 2025 Jul 1;16 (1) :5425.|Neuron. 2025 Jul 29:S0896-6273 (25) 00509-4.|Nucleic Acids Res. 2024 Aug 21:gkae707.|Oncogenesis. 2025 Aug 11;14 (1) :28.|Patent. US11576860B2.|Patent. US2019/0365645A1.|Patent. US20190365645A1.|Patent. US20190366064A1.|Research Square Preprint. 2024 Dec 04.|Research Square Print. 2022 May.|Research Square Print. 2023 Mar 1.|Rheumatology (Oxford) . 2025 Aug 13:keaf437.|STAR Protoc. 2021 May 20;2 (2) :100548.|STAR Protoc. 2021 Nov 5;2 (4) :100881.|STAR Protoc. 2022 Apr 13;3 (2) :101296.|STAR Protoc. 2023 Feb 3;4 (1) :102092.|Theranostics. 2022 Jan 1;12 (3) :1187-1203.

Chemical Information

Doxycycline Hydrochloride

Doxycycline Hydrochloride is the hydrochloride salt form of doxycycline exhibiting antimicrobial activity. Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis. In addition, this agent has exhibited inhibition of collagenase activity. (NCI)

CAS Number10592-13-9
PubChem CID54685920
IUPAC Name(4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide;hydrochloride
Molecular FormulaC22H25ClN2O8
Molecular Weight480.9
Topological Polar Surface Area182
Hydrogen Bond Donor Count7
Hydrogen Bond Acceptor Count9
Rotatable Bond Count2
Heavy Atom Count33
Formal Charge0
Complexity956
SMILES
C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.Cl
InChI
InChI=1S/C22H24N2O8.ClH/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29;/h4-7,10,14-15,17,25-27,30,32H,1-3H3,(H2,23,31);1H/t7-,10+,14+,15-,17-,22-;/m0./s1
InChIKey
PTNZGHXUZDHMIQ-CVHRZJFOSA-N
Chemical Structure
2D Structure
2D structure of Doxycycline Hydrochloride
CAS: 10592-13-9
CID: 54685920
Formula: C22H25ClN2O8
MW: 480.9
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight480.9
Hydrogen Bond Donor Count7
Hydrogen Bond Acceptor Count9
Rotatable Bond Count2
Exact Mass480.1299435
Monoisotopic Mass480.1299435
Topological Polar Surface Area182 Ų
Heavy Atom Count33
Formal Charge0
Complexity956
Isotope Atom Count0
Defined Atom Stereocenter Count6
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count2
Compound Is CanonicalizedYes

Related Products

CatalogName
HY-N0565ASDoxycycline-d3 (hydrochloride)
HY-N0565-01Doxycycline
HY-N0565B-01Doxycycline hyclate
HY-N0565R-01Doxycycline (Standard)
HY-N0565CDoxycycline (calcium)
HY-W008923-01Doxycycline (monohydrate)
HY-148124-016-epi Doxycycline
HY-110081S-01Doxycycline hyclate-d5
HY-N0565BR-01Doxycycline hyclate (Standard)
HY-W008923RDoxycycline (monohydrate) (Standard)

Alternative Products

CatalogName
C8734-100Doxycycline hydrochloride
CS-SN-00026Doxycycline-D3 Hydrochloride
447688-01Doxycycline Hydrochloride discontinued
080400-01Doxycycline Hydrochloride for Lab Use
PCT2138-01Doxycycline Hydrochloride Plant Culture Tested
286193-01Oxytetracycline Hydrochloride (Doxycycline Impurity E)
1582GR001Doxycycline hydrochloride pure EP (pharma grade)

Popular Products